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Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a progressive
metabolic disorder caused by thymidine phosphorylase (TP) enzyme deficiency.
The lack of TP results in systemic accumulation of deoxyribonucleosides thymidine
(dThd) and deoxyuridine (dUrd). In these patients, clinical features include
mental regression, ophthalmoplegia, and fatal gastrointestinal complications. The
accumulation of nucleosides also causes imbalances in mitochondrial DNA (mtDNA)
deoxyribonucleoside triphosphates (dNTPs), which may play a direct or indirect role in
the mtDNA depletion/deletion abnormalities, although the exact underlying mechanism
remains unknown. The available therapeutic approaches include dialysis and enzyme
replacement therapy, both can only transiently reverse the biochemical imbalance.
Allogeneic hematopoietic stem cell transplantation is shown to be able to restore
normal enzyme activity and improve clinical manifestations in MNGIE patients. However,
transplant related complications and disease progression result in a high mortality rate.
New therapeutic approaches, such as adeno-associated viral vector and hematopoietic
stem cell gene therapy have been tested in Tymp−/−Upp1−/− mice, a murine model
for MNGIE. This review provides background information on disease manifestations of
MNGIE with a focus on current management and treatment options. It also outlines the
pre-clinical approaches toward future treatment of the disease.
Keywords: mitochondrial neurogastrointestinal encephalomyopathy, MNGIE, thymidine phosphorylase,
metabolic disease, HSCT, HSCGT, lentiviral vector
INTRODUCTION
Mitochondrial diseases represent a genetically and clinically heterogeneous group of disorders
caused by mutations in mitochondrial DNA (mtDNA), that affect synthesis and function of
mitochondrial proteins, such as tRNA (in MELAS disease) and ND1, 4, 6 (responsible for the
majority of cases in LHON disease) (DiMauro, 2004). Another group is caused by mutations in
nuclear DNA (nDNA) that lead to defects in nuclear encoded mitochondrial proteins. Part of
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these proteins exert their effect on mtDNA maintenance,
thus known as nuclear-mitochondrial communication
disorders. A subtype of the latter is MDS; a group of mainly
autosomal recessive disorders caused by defects in nuclear genes
involved in mtDNA replication (e.g., POLG and PEO1 causing
hepatocerebal MDS), or genes crucial for maintenance of mtDNA
including TK2 (responsible for myopathic MDS), RRM2B
(encephalomypathic MDS) and thymidine phosphorylase
(TYMP) gene mutations associated with MNGIE (El-Hattab and
Scaglia, 2013). MNGIE, initially described in Okamura et al.
(1976) is a fatal rare inherited metabolic disorder without genetic
or ethnic predisposition (Gamez et al., 2005). The estimated rate
of occurrence is 1–9:1,000,0001, and as of 2011 fewer than 200
cases have been described in the medical literature (Halter et al.,
2011). Due to its variable clinical presentations, MNGIE can be
easily overlooked or misdiagnosed as Crohn’s disease, psychiatric
disorder, anorexia nervosa, or myasthenia gravis (Rickards et al.,
1994; Teitelbaum et al., 2002; Marti et al., 2004).
GENETIC DEFECTS, CLINICAL
MANIFESTATIONS, AND DIAGNOSIS
Genetic Defects
Mitochondrial neurogastrointestinal encephalomyopathy is an
autosomal recessive inherited disease that is caused by mutations
in the nuclear gene TYMP (previously known as ECGF1).
TYMP codes for the TP enzyme (EC 2.4.2.4.) and is located
on chromosome 22q13.33 (Stenman et al., 1992). TP is a
cytoplasmic enzyme expressed in most human tissues, including
gastrointestinal tract, central and peripheral nervous system,
spleen, liver, bladder, leukocytes and in platelets which account
for most of the TP activity in human blood (Fukami and
Salganicoff, 1973; Shaw et al., 1988). In contrast, TP is present at
low levels in muscles and is lacking in kidney, aorta and fat tissues
Abbreviations: AAV, adeno-associated virus; ADA-SCID, adenosine deaminase-
severe combined immunodeficiency; AHSCT, allogeneic hematopoietic stem
cell transplantation; ANT-1, adenine nucleotide translocase type 1; BBB,
blood–brain barrier; CGD, chronic granulomatous disease; CIPO, chronic
intestinal pseudo obstruction; CIS, common integration site; CNT, concentrative
nucleoside transporter; CPEO, chronic progressive external ophthalmoplegia;
dATP, deoxyadenosine triphosphate; dCTP, deoxycytidinetriphosphate; dGTP,
deoxyguanosine triphosphate; DGUOK, deoxyguanosine kinase; dNTP,
deoxyribonucleoside triphosphates; dThd, thymidine; dTTP, deoxythymidine
triphosphate; dUrd, deoxyuridine; ECGF1, platelet-derived endothelial cell
growth factor; EE-TP, erythrocyte encapsulated TP; ENT, equilibrative nucleosides
transport; ERT, enzyme replacement therapy; FBXL4, F-box and leucine-
rich repeat protein 4; FIX, coagulation factor IX; G-CSF, granulocyte colony
stimulating factor; GVHD, graft versus host disease; HSCT, hematopoietic stem
cell transplantation; HSCGT, hematopoietic stem cell gene therapy; LHON, Leber’s
hereditary optic neuropathy; LV, lentivirus; MDS, mitochondrial DNA depletion
syndrome; MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-
like episodes; MNGIE, mitochondrial neurogastrointestinal encephalomyopathy;
NT, nucleoside transporter; OLT, orthotopic liver transplantation; PEO,
progressive external ophthalmoplegia; POLG, DNA polymerase subunit gamma;
RRM2B, ribonucleotide reductase M2 B; SCID- X1, X-linked severe combined
immunodeficiency; SIN-LV, self-inactivating LV; TK2, thymidine kinase 2;
TYMP, thymidine phosphorylase; WAS, Wiskott–Aldrich syndrome; γ-RV,
gammaretrovirus.
1http://www.orpha.net/consor/cgi-bin/index.php
(Fox et al., 1995; Valentino et al., 2007). MNGIE is caused by a
variety of pathogenic homozygous or compound heterozygous
mutations in the exons or flanking regions of the TYMP gene.
Various mutations are reported to date (Stenson et al., 2014)
including deletions, single nucleotide insertions (Nishino et al.,
1999), splice site (Kocaefe et al., 2003; Szigeti et al., 2004b) and
frameshift mutations (Blazquez et al., 2005) and a homozygous
duplication mutation in exon 8 of the TYMP gene (Gamez et al.,
2005). The majority of these mutations are loss of function
mutations. Heterozygous mutation carriers are asymptomatic
with approximately 35% residual TP activity, although the plasma
nucleoside levels are similar to healthy controls (Marti et al.,
2004).
In addition, non-pathogenic polymorphisms have been
described in the TYMP gene. The A465T polymorphism
(c.1393G>A) was reported both in subjects with MNGIE like
features and control subjects (Vissing et al., 2002; Martin et al.,
2004). In some MNGIE cases there is no or mild clinical
involvement of gastrointestinal tract or skeletal muscle, despite
the presence of mutations in the TYMP gene leading to marked
reduction in TP activity, probably indicating that environmental
factors contribute to the severity of the clinical symptoms (Martin
et al., 2004; Szigeti et al., 2004b). Apart from late-onset forms of
the disease (Marti et al., 2005; Massa et al., 2009; Etienne et al.,
2012), most patients display typical MNGIE features before the
age of 20 years (Nishino et al., 2000; Teitelbaum et al., 2002).
Clinical Manifestations
Gastrointestinal and ocular involvements are usually the first
complications in this disease, although neuropathy and hearing
loss have been reported as primary symptoms in some cases
(Garone et al., 2011). Clinical symptoms are summarized in
Table 1.
Diagnosis
Detailed patient history, thorough clinical examination,
particular findings on magnetic resonance imaging (MRI) of
the brain (Figure 1), genomic DNA screening for mutations
in TYMP gene and biochemical analysis all contribute to the
diagnosis of MNGIE. Biochemical diagnosis of MNGIE includes
at least one of the following parameters (Marti et al., 2004):
(1) Increased blood plasma levels of dThd and dUrd (>3 and
>5 µmol/L, respectively). (2) Severely reduced TP enzyme
activity in buffy coat leukocytes (<8% of healthy controls;
healthy control mean TP activity equivalent to 634 nmol thymine
formed/hr/mg protein). Biochemical analysis reduces the risk
of missing the diagnosis in case of non-identified mutation
sites (Nishino et al., 2000) or in case of unclassified variants
(UV). Additionally, biochemical diagnosis contributes to the
confirmation or exclusion of the role of a UV as a cause for
MNGIE. Similarly, biochemical assessment is preferred over
clinical diagnosis since some of the classical symptoms of
MNGIE can be absent. Other frequently observed findings in
MNGIE patients include metabolic abnormalities such as lactic
acidosis, deficiency of mitochondrial respiratory chain enzymes,
mainly complex I and IV (Hirano et al., 1994; Debouverie et al.,
1997), urinary Thd and dUrd accumulation (Fairbanks et al.,
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FIGURE 1 | Brain MRI findings in MNGIE. MRI of MNGIE patient at age 16 with “typical” MNGIE phenotype. (A) T1 weighted sagital image shows cerebellar
vermis atrophy (arrow) and normal gyral pattern. (B) Axial T2 with hyperintensities in the dorsal pons and mesencephalon (arrow). (C coronal flair image, D axial T2)
Show extensive signal abnormalities in the cerebral white matter. The external capsule is involved as is the inner blade of the corpus callosum (arrow C,D). (E,F)
Extensive white matter involvement with sparing of the U-fibers (arrow).
2002; Spinazzola et al., 2002; la Marca et al., 2006) and elevated
protein levels in CSF (Bedlack et al., 2004). Infrequently, skeletal
muscle biopsies may reveal ragged red fibers, and mtDNA
analysis may reveal acquired deletions, depletions or point
mutations (Teitelbaum et al., 2002; Nishigaki et al., 2003).
PATHOGENESIS
The TP enzyme converts mitochondrial dThd and dUrd to the
nucleotide bases thymine and uridine respectively and 2-deoxy
ribose 1-phosphate (Friedkin and Roberts, 1954). This occurs in
de novo synthesis or via the salvage pathway. dThd and dUrd
are homogeneously present in cellular and plasma compartments
and they translocate between compartments through NTs. In
humans two unrelated protein families have been described
(Young et al., 2013), CNTs, an active transport system, and ENTs
responsible for passive facilitated diffusion.
The bidirectional ENTs, mainly ENT1, are ubiquitously
present on almost all cell types and mediate the uptake and eﬄux
of nucleosides (Figure 2B). Therefore, they are important for
cells that rely on the salvage pathway for supply of nucleosides,
including bone marrow cells, erythrocytes and leukocytes, brain
and muscles (Young et al., 2008). Although TP is not expressed in
all tissues, the TP expressed in circulating platelets and leukocytes
and some other tissues is essential to degrade the excess amounts
of dThd and dUrd nucleosides which are secreted into the blood
(Lara et al., 2007).
The molecular pathological mechanism in MNGIE involves
imbalanced nucleosides and nucleotide pools. Initially, loss of
function mutations in TYMP gene were identified resulting
in reduced TP activity (Nishino et al., 1999) leading to
accumulation of access amounts of the nucleoside substrates in
blood plasma, urine and almost all tissues (Spinazzola et al.,
2002; Valentino et al., 2007). It has been hypothesized that
this biochemical imbalance disturbs the equilibrium of intra-
mitochondrial dNTPs pools (Spinazzola et al., 2002) and hence
is responsible for mtDNA depletion, multiple deletions, and
point mutations associated with MNGIE (Hirano et al., 1994;
Papadimitriou et al., 1998; Nishino et al., 2000; Nishigaki et al.,
2003). Therefore, recent studies have addressed the relationship
between biochemical and dNTP pool imbalances and subsequent
mtDNA abnormalities in MNGIE. In vitro, mtDNA point
mutations and deletions, similar to those detected in MNGIE
patients were reported in cultured HeLa cells after long time
culture in the presence of high levels of thymidine in the
culture medium. These mtDNA alterations were attributed to
expanded levels of dTTP and dGTP and reduced levels of
dCTP and dATP. However, no mtDNA depletion was observed
in these HeLa cells (Song et al., 2003). Further investigation
revealed that this increase in dTTP, under similar culture
conditions, was more pronounced in non-cycling skin and
lung fibroblasts leading to depletion in mtDNA in a dThd
dose and time dependent manner (Pontarin et al., 2006).
Interestingly, mtDNA levels were recovered upon removal of
the dThd from the culture medium. In order to understand
the influence of metabolites accumulation on the creation
of mtDNA alterations, an in organello experimental model
was used. Excess amounts of dThd were responsible for the
significant increase in mitochondrial levels of dTTP, together
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FIGURE 2 | Schematic representation of autologous hematopoietic stem cell based gene therapy for MNGIE and possible mechanism of biochemical
correction by gene modified HSCs. (A) Autologous bone marrow (BM) aspirates or apheresis of peripheral blood HSCs (PBSCs) after treatment with rh-G-CSF or
plerixafor are collected from MNGIE patient. HSCs are ex vivo transduced by GMP grade lentiviral vectors containing the human TYMP transgene. Before infusion of
the transduced cells, MNGIE patients are pre-treated with non-myeloablative conditioning to allow minimal engraftment of gene modified HSCs. Selection and ex
vivo expansion of gene modified HSCs allows for transplantation of large numbers of gene modified HSCs to obviate the need for myeloablative pre-conditioning and
allows (to some degree) for assessment of safety of the gene modified HSCs prior to transplantation, for example by lentiviral vector integration analysis (reviewed in
Watts et al., 2011). (B) The enzyme thymidine phosphorylase (TP) is deficient in all tissues of MNGIE patients, which leads to accumulation of the nucleoside
substrates dThd and dUrd and depletion of the nucleotide dCTP and finally mtDNA depletion and deletion (Gonzalez-Vioque et al., 2011). Following transplantation
of gene modified HSCs and homing to bone marrow, these cells differentiate into all types of blood cells, LV genome and human TYMP transgene are integrated in
leukocyte DNA ensuring stable expression of TP. TP catalyzes the chemical reaction which breaks down the nucleosides. This process eventually leads to reduction
of systemic nucleosides accumulation. NTs mediate nucleosides transfer via passive facilitated diffusion (ENTs) and active transport (CNTs), the ubiquitous
bidirectional ENTs are depicted (Young et al., 2013). In addition, some gene modified HSCs differentiate into monocytes and may migrate to the brain giving rise to
microglia which act as a TP reservoir and cross correct the other cells in CNS.
leading to secondary TK2 inhibition mediated reduction of
dCTP nucleotides (Gonzalez-Vioque et al., 2011). Subsequent
studies confirmed these findings in in vitro fibroblast cultures
and in vivo in the Tymp−/−Upp1−/− mouse model and
suggest that the inadequate availability of dCTP accounts for
the mtDNA depletion observed in MNGIE (Gonzalez-Vioque
et al., 2011; Camara et al., 2014; Torres-Torronteras et al.,
2014).
Altogether, these studies demonstrate that indeed it is the
nucleoside accumulation and subsequent reduction of dCTP
nucleotides, rather than the deficiency of TP per se, that accounts
for the molecular and phenotypic alterations in MNGIE. An
excellent illustration of this observation is the fact that TP
expression in skeletal muscles is absent, nonetheless, some
but not all MNGIE cases were reported with skeletal muscle
mtDNA deletions, histological and oxidative phosphorylation
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abnormalities (Papadimitriou et al., 1998; Hirano et al.,
2004).
When available, although limited, analysis of postmortem
MNGIE samples is relevant and beneficial to gain knowledge
about the molecular and pathological basis of the disease. Severe
intestinal dysmotility, also known as CIPO, and weight loss are
principle presentations of MNGIE. Histopathological analysis of
MNGIE gastrointestinal samples revealed depletion in mtDNA
and mitochondrial proliferation, and consequently cell atrophy in
the muscularis propria layer of the stomach and small intestines
(Giordano et al., 2006, 2008). Additionally, loss of interstitial cells
of Cajal and morphologically abnormal muscularis propria and
ganglion cells have been reported (Zimmer et al., 2009). On the
other hand, the study of brain tissues of two MNGIE patients
revealed no pathological proliferation of glial cells nor neuronal
loss. However, the study suggested a role of TP deficiency in
impairment of BBB, which could contribute to the observed
hyperintense T2 signals on brain MRI scans (Szigeti et al., 2004a).
Nucleoside accumulation is detrimental probably during the
early course of the disease, because nucleoside clearance did
not improve mtDNA content per cell or reduce COX deficient
fibers after liver transplantation (De Giorgio et al., 2016).
Mitochondrial DNA instability is a hallmark for diseases caused
by defective nuclear genes essential for mtDNA replication
and repair (such as PEO1, POLG1,2) or maintenance of dNTP
pools (such as ANT1, TYMP) or others involved in mtDNA
homeostasis (such as FBXL4) (Young and Copeland, 2016).
Mutations in PEO1, POLG and ANT1 underlie the autosomal
dominant form of progressive external ophthalmoplegia
(adPEO), a very well-characterized mtDNA disorder involving
stalling of mtDNA replication (Van Goethem et al., 2001; Goffart
et al., 2009). Therefore, stalling of Twinkle helicase or DNA
polymerase γ could be a common pathological mechanism
underlying mtDNA instability in MNGIE, PEO and mtDNA
depletion syndrome (Hirano et al., 2001; Liu et al., 2008).
CURRENT TREATMENTS FOR MNGIE
In general, treatment of mitochondrial diseases is mainly based
on symptom management and supportive care (Pfeffer et al.,
2013). Vitamin and amino acid supplements (Tanaka et al., 1997)
and exercise therapy (Taivassalo et al., 1998) aiming to improve
mitochondrial functions are recommended for mitochondrial
myopathies. Symptomatic management of MNGIE consists of
nutritional support (Wang et al., 2015), prevention of infections
and pain relief including interventions such as celiac plexus
neurolysis and blockage of the splenic nerve (Teitelbaum
et al., 2002; Celebi et al., 2006). Since the metabolic and
mtDNA abnormalities are attributed to the systemic nucleoside
imbalances, clinical interventions focus on direct removal of
these metabolites to restore the balance or by introducing the
deficient enzyme to reduce the metabolites.
Hemodialysis and Peritoneal Dialysis
The first hemodialysis aiming to remove the excess amounts of
nucleosides from the circulation was performed in Spinazzola
et al. (2002) in two MNGIE patients followed by another in
2006. In the first two patients, significantly reduced thymidine
levels were observed shortly after hemodialysis, however this
effect was transient as thymidine levels returned to pre-dialysis
levels 3 h after dialysis (Spinazzola et al., 2002). A progressive
reduction in Thd levels below the basal levels was observed
after repetitive dialysis treatments in the third case (la Marca
et al., 2006). A MNGIE patient who had peritoneal dialysis
showed an improvement in gastrointestinal symptoms (such
as vomiting, anorexia, abdominal pain, and diarrhea) during
the continuing peritoneal dialysis for 3 years with body weight
gain, although other major symptoms including ocular and
neurological abnormalities and brain MRI signals did not change
(Yavuz et al., 2007). Another case report noted improvement
of the gastrointestinal and neurological symptoms, mainly
the mitigation of numbness in the hands, until nucleoside
levels increased again 15 months after continuous ambulatory
peritoneal dialysis (Ariaudo et al., 2014).
Enzyme Replacement Therapy
Initially, platelet infusions were performed in two MNGIE
patients to restore TP enzyme activity in the blood. This
approach showed efficient recovery of functional TP enzyme and
correction in nucleoside imbalances, however, like dialyses, these
improvements were temporary requiring multiple treatment
sessions for long-term responses. ERT is a reliable, well-tolerated
approach to replace the deficient enzyme in a variety of lysosomal
storage disorders including Gaucher, Pompe and Fabry disease,
and Sly syndrome (Wilcox et al., 2004; Burrow et al., 2007).
For MNGIE, approaches were developed to encapsulate TP in
order to prolong the half-life of circulatory TP enzyme and
reduce the immunogenic reactions. These include polymeric
nanoparticles (De Vocht et al., 2009) and erythrocytes as they
are permeable and affect the plasma metabolites, such as in
adenosine deaminase deficiency (Bax et al., 2000; Moran et al.,
2008). The EE-TP concept is under clinical development as an
orphan ERT for MNGIE with the first attempt carried out in
a MNGIE patient in Moran et al. (2008). In this approach,
autologous erythrocytes were isolated from patients and loaded
with recombinant Escherichia coli TP enzyme in vitro via hypo
osmotic dialysis. Significant clinical improvements were observed
such as the ability to walk and climb and the recovery of
sensation and the mitigation of numbness in hands and feet,
even after 23 months after termination of multiple cycles of
EE-TP (Bax et al., 2013). When using the EE-TP approach,
there is a high risk that an immunological reaction is triggered
against the bacterial TP, especially if the infusions are repeated
several times, although this has not been observed (Levene et al.,
2013).
Orthotopic Liver Transplantation
Liver transplantation is a new ERT strategy for treatment of
MNGIE patients. TP protein levels are high in healthy human
liver tissues and significantly higher than in bone marrow
cells (Boschetti et al., 2014). Recently, OLT was successfully
applied in a severely affected, 25-years old MNGIE patient
(De Giorgio et al., 2016). Steady state nucleoside balance was
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observed up to13 months post OLT. Slight improvements in
lower limb strength and brain metabolism (reduced lactate
levels) and structure (reduced cerebellar mean diffusivity
values at diffusion MRI), improved quality of life scores and
nutritional parameters, but not body weight (40 kg), were
observed up to 6 months after OLT. When ileostomy closure
was performed, the gastrointestinal (GI) functions and body
weight declined at 13 months (37 kg). Therefore, it remains
uncertain whether the mild restoration of GI function was
due to the decompressive ileostomy, instead of the OLT. In
addition, skeletal muscle mtDNA content per cell was slightly
increased after OLT. The study suggests that the damage in post-
mitotic tissues during late stages of the disease is irreversible
despite recovery of nucleoside balance. Therefore, biochemical
correction should probably be achieved prior to irreversible
damage, preferably before the intestinal symptoms appear.
Preoperative conditioning for OLT is not required. However, this
approach requires matched organ donors (which are limited),
involves transplantation related risks and requires long-term
immunosuppression which all can further affect the quality of life
of the patients.
Hematopoietic Stem Cell Transplantation
Another possibility to restore TP enzyme activity in the
circulation is by HSCT. Recently, a retrospective analysis
of all HSC transplanted MNGIE patients between 2005
and 2011 showed that only nine out of 24 patients were
alive up to 4 years after transplantation. All nine survivors
had normalized TP activity in their blood while seven of
them showed improved body mass index, gastrointestinal
symptoms and peripheral neuropathy. On the other hand,
nine MNGIE patients died mainly due to transplant-related
causes such as GVHD and graft failure, including recipients
of HLA-mismatched unrelated cord blood transplants, while
the remaining six patients died of disease progression. The
recommendations of this study included transplantation of a
sufficient number of cells, because in some patients the graft
was rejected, and to consider more closely HLA matched donor
cells, because of the large number of GVHD observed in
this retrospective study, and to transplant at an earlier age
before major organ damage has occurred (Halter et al., 2011,
2015).
The poor physical state of MNGIE patients when they
enroll HSCT trials increases the risk for transplantation related
complications caused by conditioning regimens and immune-
suppressants. Other problems may arise from the drugs used
in HSCT which are potentially harmful to mitochondria such
as cyclophosphamide (Mariana Ponte Cardoso et al., 2015).
Therefore, MNGIE patients are treated with Busulfan and
fludarabine prior to HSCT, following the recommendations of
MNGIE consensus meeting in Halter et al. (2011). For MNGIE
patients who develop liver cirrhosis, allogeneic HSCT (AHSCT)
should be contraindicated and OLT would be the treatment
of choice (Finkenstedt et al., 2013). Pre-existing liver cirrhosis
complicates liver failure which may develop after AHSCT due to
multiple factors such as viral infections in immunocompromised
recipients or due to hepatotoxic conditioning drugs.
PRE-CLINICAL EXPERIMENTAL
APPROACHES TOWARD THERAPY
Models of MNGIE
In organello experiments and human MNGIE fibroblasts were
used for highlighting parts of the molecular mechanism of
MNGIE (Gonzalez-Vioque et al., 2011; Camara et al., 2014).
To study therapeutic interventions, such as gene therapy, in
vivo models are required. A mouse model was developed by
targeted disruption of exon 4 of the TYMP gene to generate
Tp−/− mice. In contrast to human TP, murine TP degrades
both dThd and dUrd; Tp−/− mice were crossed with Upp1−/−
to generate the Tymp−/−Upp1−/− mice, which are currently
the only relevant in vivo animal model (Haraguchi et al., 2002;
Lopez et al., 2009). Tymp−/−Upp1−/− mice show increased
levels of the purine nucleosides dThd and dUrd in plasma and
tissues. Diffuse leukoencephalopathy manifests late during the
lifetime of these animals, around the age of 22 months (Lopez
et al., 2009). Other symptoms associated with MNGIE, such
as decreased motor coordination and gastrointestinal features
have not been reported in this mouse model. Brain mtDNA
depletion was not consistently found in this mouse model
(Lopez et al., 2009; Torres-Torronteras et al., 2011; Camara
et al., 2014). Therefore, high doses of exogenous nucleosides
were administered to exacerbate the mitochondrial phenotype
(Garcia-Diaz et al., 2014), an approach that was rationalized by
the lower nucleoside levels in Tymp−/−Upp1−/− mice compared
to MNGIE patients. Mice were on an exogenous dThd and dUrd
diet for a long time (24 months) before pronounced mtDNA
depletion, diffuse leukoencephalopathy and motor abnormalities
were observed.
Experimental approaches have been explored for treatment
of MNGIE; among which experiments performed by Camara
et al. (2014) which suggest that modulation of dNTP metabolism
through increasing the availability of dCTP or inhibition of
its catabolism can indeed reverse and prevent, at least, dCtd
imbalance. A strategy that can be applied for other similar
mitochondrial disorders that are caused by altered nucleosides
and dNTP metabolism, for example in disorders caused by
mutations in TK2 or DGUOK deficiency (Camara et al., 2014).
Gene Therapy
The Tymp−/−Upp1−/− mouse model has also been used for
testing potential curative treatments. A recently investigated
strategy is the use of gene therapy. Both lentiviral (LV) and adeno-
AAV vector mediated TYMP gene transfer have been evaluated in
pre-clinical studies for treatment of MNGIE.
AAV-Mediated Liver Directed Gene Therapy
Adeno-associated viral vector gene therapy has been explored
in clinical trials for a variety of inherited and acquired diseases
(Naldini, 2015). The main limitation of this approach is the
human immune response to AAV capsid, as demonstrated in
hemophilia B trials. In one of the first AAV trials targeting the
liver, therapeutic levels of FIX were achieved at a high vector dose
(2 × 1012 vector genomes per kilogram of body weight, vg/kg).
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Nonetheless, this high vector dose was associated with an early
decline of FIX (∼8 weeks after treatment) due to T-cell immunity
against AAV capsid antigens eliminating transduced hepatocytes
(Manno et al., 2006).
The hybrid vector AAV2/8 with modified molecular
configuration (packaged double stranded genome) and improved
cassette design (codon optimized hFIX) to enhance transduction
and translational efficiency was explored in a hemophilia B
trial (Nathwani et al., 2006). Stable FIX expression diminished
use of the costly FIX concentrate and importantly, clinical
improvement was achieved in a dose dependent manner. The
least bleeding episodes were seen in recipients of the highest
AAV dose (steady state 5% of normal levels at a single vector
peripheral vein infusion of 2 × 1012 vg/kg up to 4 years)
(Nathwani et al., 2014). For MNGIE, an AAV2/8 expressing
human TYMP under the control of hepatic promoter was used
for treatment of Tymp−/−Upp1−/− mice (Torres-Torronteras
et al., 2014). Low AAV doses (2 × 1011 vg/kg ) were sufficient to
reduce nucleoside imbalances to normal levels in liver, skeletal
muscle, and brain for up to 8 months, while higher doses reduced
nucleosides below detection levels. However, only at higher doses
(>2 × 1011 vg/kg) TP activity was increased in the liver (but not
in skeletal muscle or brain).
In light of the clinical data of the hemophilia B trial which
shows that clinical improvement was AAV dose dependent
(Nathwani et al., 2014), the question for MNGIE is whether
or not the low AAV dose would be sufficient to reverse
a clinical phenotype beyond biochemical correction. MNGIE
mouse studies failed to report any relevant clinical phenotype
in Tymp−/−Upp1−/− mice, and therefore the potential or
required dosage to cure it has not been demonstrated (Torres-
Torronteras et al., 2011, 2014). Importantly, upon AAV treatment
nucleosides accumulation was not reduced in the intestine of
treated mice at the highest dose (1013 vg/kg) administered.
Since the intestines are heavily affected in MNGIE patients it
is important to obtain evidence of correction in this organ.
Preclinical studies in hemophilic dogs and non-human primates
could predict the therapeutic dose in human trials (Manno et al.,
2006; Nathwani et al., 2014) if that is the case for MNGIE too,
biochemical correction in the intestine might require improved
expression cassettes to enhance protein production, targeting
the expression to major affected organs, or the less favorable
option of using higher AAV doses (>1013 vg/kg). High doses,
for example 7.2 × 1012 vg/mouse were sufficient to transduce
100% of mouse hepatocytes (Nakai et al., 2005). Such high
doses might be required for gene therapy of systemic diseases,
i.e., when non-hepatic tissues are also affected, as in MNGIE.
However, these high AAV doses are likely to cause hepatocellular
toxicity, biodistribution to other unwanted organs and shedding
of the AAV, enhanced risk of eliciting immunity toward the viral
capsid and increased costs of virus production. Immunity against
ectopic TP might be an additional concern for MNGIE patients,
therefore prophylactic immunosuppression might be required.
Additional pre-clinical studies have to address the possibility of
an immune response against ectopic TP in previously untreated
patients. In addition to increased liver TP activity correlating
with vector dose, an unexpected increase in liver dGTP of
Tymp−/−Upp1−/− mice was observed in a dose depend manner
as well, although the consequences of this increase are unknown.
Together these findings suggest that studies into optimal dosing
of AAV may be required for clinical application.
Human AAV trials should be carried out cautiously as they can
reveal complications that were not observed during preclinical
studies. An example is the early decline in FIX expression (Manno
et al., 2006) and hepatotoxicity observed in 4/6 recipients of a
high AAV dose (2 × 1012 vg/kg) (Nathwani et al., 2014), due
to immunity against AAV capsid. MNGIE patients are often
>12 years and probably have been pre-exposed to AAV and
consequently can mount strong immune responses to AAV.
Therefore, individuals with neutralizing antibodies to AAV
should be excluded from clinical trials to avoid an immune
response toward AAV. Another concern is the durability of
transgene expression considering the longer lifespan of humans,
compared with the animals in preclinical studies, and the
potential need for recurrent AAV injections, especially at lower
vector doses. In this respect HSCGT would provide a preferable
option as a single, long lasting intervention method. Additional
concerns related to AAV mediated gene therapy include purity of
AAV preparations and manufacturing costs (Mingozzi and High,
2013).
LV-Mediated Hematopoietic Stem Cell Gene Therapy
(HSCGT)
The encouraging therapeutic outcomes and favorable safety
profile renders LV-HSCGT an attractive therapeutic approach
for a variety of hereditary metabolic disorders (Wagemaker,
2014), and is potentially advantageous over AHSCT for certain
selected diseases (Naldini, 2015). Proof of concept of HSC
gene therapy was obtained in Tymp−/−Upp1−/− mice (Torres-
Torronteras et al., 2011) using a phosphoglycerate kinase
promoter driving native human TYMP cDNA and a GFP reporter
in hematopoietic cells resulting in biochemical correction in
peripheral blood (Torres-Torronteras et al., 2011). More recently,
we developed clinically applicable LVs that carry human TYMP
cDNA, and demonstrated long-term biochemical correction in
Tymp−/−Upp1−/− mice at low vector copy number (VCN).
Our data demonstrates the feasibility to further develop clinical
protocols for HSCGT for MNGIE (Yadak et al., 2015). Similar
results in a long-term follow up of 20 months confirms the
correction of biochemical imbalances which was maintained at
low VCN and chimerism (Torres-Torronteras et al., 2016).
In HSCGT for MNGIE, HSCs are isolated from MNGIE
patients, transduced ex vivo by LV vectors carrying a functional
copy of TYMP and infused back into the patient (Figure 2A).
The newly formed HSCs and its progenitors produce TP which
catabolize the excess amounts of nucleosides (Figure 2B). Since
the patient’s own stem cells are used, GVHD is not a concern.
However, mild prophylactic immunosuppression maybe required
to prevent possible immune reaction against the TP transgene.
Myeloablative pre-conditioning might be necessary for high
levels of engraftment in other metabolic disorders, such as
metachromatic leukodystrophy (MLD), due to lack of selective
advantage of gene modified cells. In particular, busulfan
myeloablative conditioning is used in MLD patients for depletion
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 February 2017 | Volume 11 | Article 31
fncel-11-00031 February 13, 2017 Time: 17:57 # 9
Yadak et al. Pathogenesis, Current and Prospective Treatments for MNGIE
of endogenous microglia and mobility of gene modified
monocytes through the BBB (Capotondo et al., 2012). The
contribution of gene modified microglia to correct biochemical
imbalances has never been explored in MNGIE. However,
murine gene therapy studies using LV and AAV vectors
implicate reversal of nucleoside imbalance at low or possibly
no increase in brain TP activity (Torres-Torronteras et al.,
2014, 2016). In liver directed AAV2/8 gene therapy, it is
not expected that brain cells will be transduced. In HSCGT,
gene modified monocytes are expected to migrate to brain
and differentiate into microglia. Nonetheless, the results of the
HSCGT MNGIE mouse study do not rule out the potential
that gene modified microglia can contribute to correction of
brain biochemistry and phenotype, although this might not
be necessary if ectopic expression outside the brain is high
enough. When transduction efficiency is high enough, significant
TP activity can be measured in the brain, indicating that
transduced microglia might reside in the brain after long-term
follow-up. To that end, two potential mechanisms might act
synergistically to normalize the brain nucleoside levels, a systemic
ectopic source and one local contribution of gene-modified cells
(Figure 2B).
Potential options and future research for application in
MNGIE patients include alternative conditioning strategies to
obviate the cytotoxicity related to myeloablative conditioning and
strategies to enhance the quality of infused gene modified HSCs.
One approach is to mobilize endogenous HSCs into peripheral
blood in order to create (space) in the bone marrow for the
infused donor HSCs to engraft (Chen et al., 2006). Human
G-CSF was sufficient in immunocompromised mice (Huston
et al., 2014), probably due to the selective advantage of the
gene modified cells, however, more stringent agents might be
required in normal immunocompetent mice. A possibility is
G-CSF in combination with the more potent HSCs mobilizer
plerixafor (a specific CXCR4 antagonist) or the selectins inhibitor
fucoidan. Such regimens probably require additional mild
chemotherapeutics, in particular if the gene corrected TP-
expressing HSCs lack selective growth advantage to overcome
host cells. These HSCs mobilizers act via different mechanisms,
therefore parameters such as the optimal dose and time frame
for transplantation after mobilization need to be established
in relevant pre-clinical models. Alternatively, targeting specific
endogenous hematopoietic populations might reduce the off-
target toxicity related to the common non-specific conditioning
(Aiuti and Naldini, 2016). Examples include inhibiting c-kit, a
HSC tyrosine kinase cell surface antigen (Xue et al., 2010) and
the recently developed immunotoxin against hematopoietic stem
cells (CD45-SAP) (Palchaudhuri et al., 2016).
Strategies such as ex vivo expansion of gene modified HSCs
can improve the quality of the infused gene modified cells
and enhance the outcome of gene therapy (Watts et al., 2011).
In particular when combined with additional approaches to
enrich for HSCs, preserve stemness of- and enhance homing
and engraftment ability of gene modified HSCs (Psatha et al.,
2016). Ultimately, this approach combined with improved mild
pre-conditioning protocols, could benefit patients in poor health
condition at transplantation, such as in MNGIE patients.
A risk of HSC gene therapy is insertional mutagenesis. The
first HSC gene therapy trials used gammaretrovirus (γ-RV) based
vectors for treatment of SCID-X1 (Gaspar et al., 2004; Hacein-
Bey-Abina et al., 2010), adenosine deaminase (ADA-SCID) (Aiuti
et al., 2002), CGD (Ott et al., 2006) and WAS (Boztug et al., 2010).
Although efficient correction of immunodeficiency was achieved
in most patients in SCID-X1, CGD and WAS trials, lympho-
proliferative disorders (Hacein-Bey-Abina et al., 2003a,b, 2008;
Howe et al., 2008; Braun et al., 2014) and myelodysplasia (Stein
et al., 2010) developed secondary to γ-RV vector integrations
within or nearby proto-oncogenes. In addition to the preferred
integration profiles over γ-RV vector (Deichmann et al., 2007;
Cattoglio et al., 2007; Gabriel et al., 2012), LV efficiently
transduce non-cycling primitive HSCs and under minimum
culture conditions (Naldini et al., 1996; Guenechea et al., 2000).
Therefore, attention was focused on development of LV as a
relatively safer approach, leading eventually to development of
third-generation SIN-LV (Dull et al., 1998; Zufferey et al., 1998).
Several pre-clinical studies indicate the reduced genotoxicity of
SIN-LV vectors compared with γ-retroviral vectors, in particular
SIN-LV CISs revealed no preference of integration near proto-
oncogenes (Montini et al., 2006; Modlich et al., 2009; Biffi
et al., 2011; Romero et al., 2013; Zhou et al., 2013). Since
then, SIN-LV vectors have been applied successfully in ongoing
clinical trials for a variety of metabolic (Cartier et al., 2009; Biffi
et al., 2013) and immunodeficiency disorders (Aiuti et al., 2013),
and no adverse events have yet been reported in these trials.
Moreover, the therapeutic benefits without toxicity related to
transgene expression and biosafety of SIN-LV vectors has been
further validated through a growing body of recent preclinical
studies supporting the initiation of clinical trials, for example for
β-thalassemia (Negre et al., 2015) and mucopolysaccharidosis I
disease (Visigalli et al., 2016).
Furthermore, selective advantage for growth and
differentiation conferred by the therapeutic transgene expression
increases the potential risk for proliferative disorders, this
was reported in some immunodeficiency conditions (Aiuti
and Roncarolo, 2009). For metabolic disorders, for instance
lysosomal storage disorders, however, most studies show that
enzyme positive cells have no selective advantage (Bernardo and
Aiuti, 2016), which is most likely the case in MNGIE as well.
To improve safety, technologies such as ex vivo expansion of
gene modified HSCs may permit for safety assessment (to some
degree) prior to transplantation, by analysis of LV integration
sites (Watts et al., 2011; Figure 2A).
AAV Mediated GT or HSCGT?
Regardless of the type of viral vector used for gene therapy, the
chosen strategy should provide long-term expression of the gene
of interest without side effects in the host. It is important to
apply a well-defined vector dose that is sufficient to reverse the
biochemical and nucleotide imbalance without any potential side
effects. In particular, abnormal overexpression of the TP enzyme
is detected in different tumor types, including non-small cell
lung-, colorectal-, breast-, gastrointestinal-, and hepatic cancers
(Koukourakis et al., 1997; Mori et al., 2000; Ikeguchi et al., 2001;
Nakayama et al., 2005; Mitselou et al., 2012) and correlates with a
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worse prognosis in colorectal cancer patients (Takebayashi et al.,
1996). Besides, disturbance of dNTP pools can be a trigger for cell
cycle arrest and apoptosis (Oliver et al., 1996; Kumar et al., 2010).
The medical condition of the patient can also influence the
choice of the vector system for clinical application. For terminally
ill patients, the AAV approach could be most suitable to avoid
the risks associated with the pre-conditioning for transplantation
in autologous HSC gene therapy or if a suitable HSCs donor for
AHSCT is lacking.
CONCLUDING REMARKS
The lack of mitochondrial histone protection, the limited repair
capacity and oxidized dNTPs contributing to mismatch errors
(Alexeyev et al., 2013) all make mitochondria more susceptible
than nuclear DNA to mutagenesis. It has become evident that
it is the systemic accumulation of nucleosides in MNGIE (Di
Meo et al., 2015) that causes imbalances in mitochondrial dNTP
pools. However, the mechanism by which it causes mtDNA
alterations is still unknown. Although the current treatments
focus on restoration of TP enzyme activity and/ or elimination
of accumulating metabolites, further understanding of cellular
mechanisms involved in maintenance of mtDNA integrity and
copy number can provide targets for clinical intervention for
MNGIE and possibly other mitochondrial disorders.
Platelet infusions, hemato/peritoneal dialysis, and EE-TP
ERT could be used to provide biochemical correction. AAV
gene therapy and lentiviral HSCGT are potential curative
options as evidenced by the promising pre-clinical results
in Tymp−/−Upp1−/− mice. OLT is a promising emerging
treatment and should currently be the treatment of choice
for MNGIE patients with pre-existing liver failure. Allogeneic
HSCT has risks of graft failure, GVHD and conditioning-related
toxicity. Milder conditioning may be applicable in HSCGT, and
treatment should preferably be applied at an early age. Novel
strategies are being explored to improve the safety and efficiency
of viral based gene therapy, ultimately for MNGIE patients as
well. These include strategies to enhance transduction, improve
engraftment of gene modified HSCs and limit transplantation
related toxicity, and others to overcome the limitation of AAV
capsid triggered immunity by means of novel serotypes and
improved transcription cassettes.
Mitochondrial neurogastrointestinal encephalomyopathy
patients should receive suitable treatment promptly before
permanent damage occurs, which can be challenging, as MNGIE
patients are often diagnosed late during disease progression in a
poor health condition. Because TP activity and nucleoside levels
can be routinely measured in blood samples, MNGIE should
be considered to be included in newborn screening programs,
similar to other (neuro) metabolic disorders for early diagnosis
and treatment (Carlson, 2004; McHugh et al., 2011).
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